Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Leukemia

Free Subscription 16.02.2026 1 Am J Hematol 5 Ann Hematol 2 Biochem Pharmacol 1 BMC Cancer 1 Bone Marrow Transplant 1 Cancer 1 Cancer Lett 1 Exp Hematol 1 J Biol Chem 1 J Pediatr Hematol Oncol 4 Leuk Lymphoma 2 Leuk Res 2 Leukemia

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. JONES MK, Sanchez J, Connor M, Julian K, et al
   Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.
   Am J Hematol. 2026 Feb 13. doi: 10.1002/ajh.70231.
   PubMed         Abstract available
   
   

   
   Ann Hematol

2. BUDZISZEWSKA BK, Lomiak M, Barankiewicz J, Patkowska E, et al
   Comprehensive geriatric assessment (CGA) scale does not effectively identify elderly AML patients suitable for intensive induction chemotherapy - a multicenter study from Polish Adult Leukemia Group.
   Ann Hematol. 2026;105:114.
   PubMed        
   
   
3. MA Y, Cheng Y, Sun Y, Zhu X, et al
   Short-course high-dose cytarabine consolidation therapy before allogeneic hematopoietic stem cell transplantation improves 2-year relapse-free survival but not overall survival in patients with acute myeloid leukemia: a single-center retrospective stu
   Ann Hematol. 2026;105:113.
   PubMed         Abstract available
   
   
4. JIANG B, Li J, Liu L, Du X, et al
   Correction to: Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
   Ann Hematol. 2026;105:108.
   PubMed        
   
   
5. ZHANG T, Liu D, Ren F, Hao J, et al
   Chronic lymphocytic leukemia with IGH/BCL2 fusion and clonal heterogeneity: phenotypic and molecular profiling analysis of a rare case.
   Ann Hematol. 2026;105:105.
   PubMed         Abstract available
   
   
6. YUAN R, Xie Y, Miron PM, Higgins AW, et al
   Clinico-genomic characterization of RAS-mutant acute myeloid leukemia.
   Ann Hematol. 2026;105:99.
   PubMed         Abstract available
   
   

   
   Biochem Pharmacol

7. THIBODEAU J, Zhao J, Edwards H, Polin L, et al
   Loss of cystathionine-beta-synthase contributes to elevated OXPHOS, a vulnerability in ara-C-resistant myeloid Leukemia in Down syndrome.
   Biochem Pharmacol. 2026 Feb 13:117815. doi: 10.1016/j.bcp.2026.117815.
   PubMed         Abstract available
   
   
8. YANG J, Ren J, Tao T, Peng M, et al
   Mutant NPM1-regulated estrogen signaling promotes leukemia cell survival by upregulating HGF and represents a therapeutic vulnerability.
   Biochem Pharmacol. 2026;247:117796.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. CHENG F, Wang F, Cui Z, Li Q, et al
   Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.
   BMC Cancer. 2026 Feb 11. doi: 10.1186/s12885-026-15719.
   PubMed        
   
   

   
   Bone Marrow Transplant

10. NAVARRO V, Iacoboni G, Camarillas S, Carpio C, et al
    CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2026 Feb 14. doi: 10.1038/s41409-026-02803.
    PubMed         Abstract available
    
    

    
    Cancer

11. DINARDO CD, Croden J, Abdel-Salam HM, Kadia T, et al
    Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.
    Cancer. 2026;132:e70315.
    PubMed         Abstract available
    
    

    
    Cancer Lett

12. PHILIPPE C, Jaud M, Da Cunha C, Van Den Berghe L, et al
    The endoplasmic reticulum stress-regulated XBP1s transcription factor drives a negative feedback loop on FLT3 expression in leukemia cells.
    Cancer Lett. 2026 Feb 10:218310. doi: 10.1016/j.canlet.2026.218310.
    PubMed        
    
    

    
    Exp Hematol

13. YAN Y, Kato H, Sano S, Furukawa E, et al
    Heme Synthesis Inhibition Induces the Intrinsic Apoptosis Pathway in Leukemia with OSGIN1 Upregulation.
    Exp Hematol. 2026 Feb 13:105401. doi: 10.1016/j.exphem.2026.105401.
    PubMed         Abstract available
    
    

    
    J Biol Chem

14. MICHAIL C, Berthelet J, Mechaly AE, Bui LC, et al
    The SETD2 L1609P mutation found in leukemia disrupts methyltransferase activity and reduces histone H3K36 trimethylation.
    J Biol Chem. 2026 Feb 5:111259. doi: 10.1016/j.jbc.2026.111259.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

15. FAJARDO AF, Cox S, MacDonald P, Athale U, et al
    Use of Universal Premedication in the Prevention of Allergic Reactions to PEGylated-Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
    J Pediatr Hematol Oncol. 2026 Feb 11. doi: 10.1097/MPH.0000000000003164.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

16. CLAIBORNE JP, Tsai HL, Ghiaur G, Smith BD, et al
    Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2026 Feb 15:1-14. doi: 10.1080/10428194.2026.2628206.
    PubMed         Abstract available
    
    
17. AHMED VR, Rahman FM
    NOTCH1 and SF3B1 mutations in chronic lymphocytic leukemia with their clinical associations.
    Leuk Lymphoma. 2026 Feb 14:1-8. doi: 10.1080/10428194.2026.2626937.
    PubMed         Abstract available
    
    
18. LI B, Chen Y, Chen S, Zheng Z, et al
    Risk prediction model and survival analysis of adult patients with intracranial hemorrhage in acute leukemia.
    Leuk Lymphoma. 2026 Feb 11:1-10. doi: 10.1080/10428194.2026.2624658.
    PubMed         Abstract available
    
    
19. CUI D, Tao Y, Zhang Y, Luo J, et al
    Clinical characteristics and treatment outcomes of pediatric Philadelphia chromosome positive acute lymphoblastic leukemia: a comparative analysis of p190 and p210 subtypes in the TKI era.
    Leuk Lymphoma. 2026 Feb 8:1-8. doi: 10.1080/10428194.2026.2624661.
    PubMed         Abstract available
    
    

    
    Leuk Res

20. CHANG G, Gao H, Wei Y, Fu Q, et al
    Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Leuk Res. 2026;163:108187.
    PubMed         Abstract available
    
    
21. WANG WJ, Wang SA, Al-Atrash G, Fang H, et al
    T-cell mixed chimerism after allogeneic hematopoietic stem cell transplantation does not correlate with relapse in patients with acute myeloid leukemia.
    Leuk Res. 2026;162:108185.
    PubMed        
    
    

    
    Leukemia

22. NIELSEN CG, Als-Nielsen B, Albertsen BK, Davidsson OB, et al
    Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.
    Leukemia. 2026 Feb 10. doi: 10.1038/s41375-026-02873.
    PubMed         Abstract available
    
    
23. MECKLENBRAUCK R, Villaverde Ramiro A, Strang E, Gabdoulline R, et al
    Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.
    Leukemia. 2026 Feb 9. doi: 10.1038/s41375-026-02874.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum